Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
What: Shares of biotech Theravance
So what: GlaxoSmithKline is investing roughly $213 million in the smaller company in a deal that gives it 10 million new shares through a private placement at a price of $21.29 each, a 9% premium to Friday's closing price. That brings GlaxoSmithKline's stake up to 25.8 million shares, or almost 27% of Theravance.
Now what: The two companies are currently partnering to develop Relovair, an experimental drug for lung disease and asthma. The pair has been collaborating for a decade and the investment signifies further confidence in Theravance. Relovair is seen as the follow-up successor to GlaxoSmithKline's Advair asthma drug, and Relovair has already completed phase 3 development.
Interested in more info on Theravance? Add it to your watchlist by clicking here.
